NCT07317440

Coenzyme Q10 in Pediatric Community-Acquired Pneumonia

Coenzyme Q10 as an Adjunct Therapy in Pediatric Community-Acquired Pneumonia

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Tanta University · Academic / Other
• Sex: All
• Age: 2 Months – 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of this work is to assess the benefit of coenzyme Q10 supplementation, in addition to standard antibiotic and other supportive therapy, in the management of hospitalized children with community acquired pneumonia

Conditions

• Community Acquired Pneumonia

Interventions

Type	Name	Description
DRUG	oral coenzymeQ10	60 children with community acquired pneumonia will receive oral coenzymeQ10 in capsule form at a dose of 100-200 mg/kg/day, as adjunct therapy to the usual pneumonia treatment till the recovery of the disease.

Timeline

• Start date: 2025-12-31
• Primary completion: 2026-06-01
• Completion: 2026-12-31
• First posted: 2026-01-05
• Last updated: 2026-01-05

Locations

1 site across 1 country: Egypt